Published in
American Association for the Advancement of Science, Science Translational Medicine, 548(12), 2020
DOI: 10.1126/scitranslmed.abc4220
Links
Tools
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
Journal article published in 2020 by
Sangeeta Goswami 
,
Yulong Chen,
Swetha Anandhan ,
Peter M. Szabo,
Sreyashi Basu ,
Jorge M. Blando ,
Wenbin Liu,
Jan Zhang,
Seanu Meena Natarajan,
Liangwen Xiong,
Baoxiang Guan,
Shalini Singh Yadav ,
Abdel Saci ,
James P. Allison ,
Matthew D. Galsky
and other authors.
,
Yulong Chen,
Swetha Anandhan ,
Peter M. Szabo,
Sreyashi Basu ,
Jorge M. Blando ,
Wenbin Liu,
Jan Zhang,
Seanu Meena Natarajan,
Liangwen Xiong,
Baoxiang Guan,
Shalini Singh Yadav ,
Abdel Saci ,
James P. Allison ,
Matthew D. Galsky
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
A combination of ARID1A mutation and CXCL13 expression in baseline tumor tissues improves predictive capability for patients with mUCC receiving ICT.